Home > News content

[medical health weekly] week 24: the medical device R & D company "Hongtong industry" completed a strategic financing of RMB 586million, and the gastrointestinal and airway stent m...

via:凤凰网     time:2022/6/21 13:01:24     readed:71

Focus, point, guide and read

There are 49 global investment and financing projects in the field of health care, including 30 domestic financing and 19 foreign financing. In terms of financing, there are 12 financing in the field of domestic medical devices and hardware, ranking first, and 6 financing in the field of medicine, ranking second; There are 8 financing cases in the field of medical informatization abroad, ranking first, and 4 cases in the fields of biotechnology, medical devices and hardware, ranking second.

In terms of domestic investment and financing, in the field of medical devices and hardware, the medical device R & D company "Hongtong industry" obtained 586million yuan of strategic round financing, and the liquid chromatography product manufacturer "Hanbang technology" obtained more than 300million yuan of round C financing.

In terms of foreign investment and financing, in the field of medical devices and hardware, m.i.tech, a manufacturer of gastrointestinal and airway stents, was acquired with about US $230million; In the field of medical informatization, aidoc medical, a medical imaging artificial intelligence auxiliary analysis institution, obtained a round D financing of US $110million.

From June 13, 2022 to June 19, 2022, the global primary market database of titanium media tmtbase recorded a total of 49 domestic and foreign investment and financing events of medical and health racetracks, including 30 domestic financing and 19 foreign financing.

Domestic one week financing trends

✔.In the past week, the global primary market database of titanium media tmtbase recorded a total of 30 investment and financing events in the domestic medical and health field, with a month on month increase of 11.1%.

✔. In terms of financing quantity, there were 12 cases in the field of medical devices and hardware, and 6 cases in the field of medicine,There are 5 cases in the field of biotechnology, 3 cases in the field of medical services, 2 cases in the field of medical informatization and 2 cases in the field of consumer medicine.

✔. From the perspective of financing quantity, from the first seed round,There are 2 pre-A rounds, 3 a rounds, 1 B round, 2 C rounds, 1 D round, 17 strategic investments and 3 mergers and acquisitions.

✔. In the past week, a total of 5 projects with financing amount above 100 million yuan were disclosed, including 1 in the pharmaceutical field and 4 in the medical devices and hardware field.

Domestic titanium Media Pro · recommended projects

Medical devices and hardware

"Hongtong industry" completed 586million yuan of strategic financing

A few days ago, Hongtong industry, a medical device product R & D provider, completed 586million yuan of strategic financing, with huitai medical as the investor. Huitai medical devices is a supplier of minimally invasive cardiovascular intervention medical devices. The company's business integrates R & D, production and sales. It mainly deals in physiological electrode catheter, catheter sheath with hemostatic valve, three-dimensional equipment and other cardiovascular and cerebrovascular intervention products.

It is understood that Hongtong industry is a medical device product R & D business. Its products include: multi-channel electrophysiological equipment, three-dimensional navigation mapping system, radio frequency instrument, etc. According to incomplete statistics, there were 82 financing transactions in the field of medical health of Hongtong industry this year.

medicine

"Kemo medicine" completed the round a financing of 150million yuan

Recently, Kemo pharmaceutical completed a round of financing of 150million yuan. This round of financing is led by the listed company Zhejiang sapus Pharmaceutical Co., Ltd. and followed by Jinyu Bogor, Bangsheng capital, Huzhou Chunsheng and other institutions. The funds will be used for the construction of Komo pharmaceutical R & D headquarters, and continue to promote the construction of Komo pharmaceutical's one-stop innovative pharmaceutical cro service platform and team.

Komo bio is a pharmaceutical R & D solution provider and an innovative cro platform company, committed to providing one-stop and customizable pharmaceutical R & D solutions for global biotechnology and pharmaceutical enterprises.

translate engine: baidu

China IT News APP

Download China IT News APP

Please rate this news

The average score will be displayed after you score.

Post comment

Do not see clearly? Click for a new code.

User comments